vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.

OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $12.1M, roughly 1.1× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs -488.0%, a 556.7% gap on every dollar of revenue. On growth, TRANSCONTINENTAL REALTY INVESTORS INC posted the faster year-over-year revenue change (2.3% vs -22.4%). Over the past eight quarters, TRANSCONTINENTAL REALTY INVESTORS INC's revenue compounded faster (0.7% CAGR vs -5.3%).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.

OCUL vs TCI — Head-to-Head

Bigger by revenue
OCUL
OCUL
1.1× larger
OCUL
$13.3M
$12.1M
TCI
Growing faster (revenue YoY)
TCI
TCI
+24.7% gap
TCI
2.3%
-22.4%
OCUL
Higher net margin
TCI
TCI
556.7% more per $
TCI
68.8%
-488.0%
OCUL
Faster 2-yr revenue CAGR
TCI
TCI
Annualised
TCI
0.7%
-5.3%
OCUL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OCUL
OCUL
TCI
TCI
Revenue
$13.3M
$12.1M
Net Profit
$-64.7M
$8.3M
Gross Margin
88.0%
Operating Margin
-526.5%
-28.9%
Net Margin
-488.0%
68.8%
Revenue YoY
-22.4%
2.3%
Net Profit YoY
-33.6%
7577.8%
EPS (diluted)
$-0.27
$0.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
TCI
TCI
Q4 25
$13.3M
$12.1M
Q3 25
$14.5M
$12.8M
Q2 25
$13.5M
$12.2M
Q1 25
$10.7M
$12.0M
Q4 24
$17.1M
$11.8M
Q3 24
$15.4M
$11.6M
Q2 24
$16.4M
$11.8M
Q1 24
$14.8M
$11.9M
Net Profit
OCUL
OCUL
TCI
TCI
Q4 25
$-64.7M
$8.3M
Q3 25
$-69.4M
$724.0K
Q2 25
$-67.8M
$169.0K
Q1 25
$-64.1M
$4.6M
Q4 24
$-48.4M
$108.0K
Q3 24
$-36.5M
$1.7M
Q2 24
$-43.8M
$1.5M
Q1 24
$-64.8M
$2.5M
Gross Margin
OCUL
OCUL
TCI
TCI
Q4 25
88.0%
Q3 25
87.8%
Q2 25
85.6%
Q1 25
88.2%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
90.8%
Q1 24
91.0%
Operating Margin
OCUL
OCUL
TCI
TCI
Q4 25
-526.5%
-28.9%
Q3 25
-472.3%
-10.9%
Q2 25
-502.6%
-6.8%
Q1 25
-597.5%
-5.3%
Q4 24
-296.1%
-14.3%
Q3 24
-298.2%
-14.4%
Q2 24
-265.1%
-9.2%
Q1 24
-214.0%
-11.2%
Net Margin
OCUL
OCUL
TCI
TCI
Q4 25
-488.0%
68.8%
Q3 25
-477.3%
5.6%
Q2 25
-503.9%
1.4%
Q1 25
-598.7%
38.5%
Q4 24
-283.3%
0.9%
Q3 24
-236.6%
14.7%
Q2 24
-266.3%
12.7%
Q1 24
-438.9%
21.4%
EPS (diluted)
OCUL
OCUL
TCI
TCI
Q4 25
$-0.27
$0.97
Q3 25
$-0.38
$0.08
Q2 25
$-0.39
$0.02
Q1 25
$-0.38
$0.53
Q4 24
$-0.25
$0.01
Q3 24
$-0.22
$0.20
Q2 24
$-0.26
$0.17
Q1 24
$-0.49
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
TCI
TCI
Cash + ST InvestmentsLiquidity on hand
$737.1M
$89.0M
Total DebtLower is stronger
$210.8M
Stockholders' EquityBook value
$654.3M
$846.7M
Total Assets
$808.1M
$1.1B
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
TCI
TCI
Q4 25
$737.1M
$89.0M
Q3 25
$344.8M
$82.7M
Q2 25
$391.1M
$73.5M
Q1 25
$349.7M
$88.6M
Q4 24
$392.1M
$99.7M
Q3 24
$427.2M
$131.6M
Q2 24
$459.7M
$127.5M
Q1 24
$482.9M
$130.8M
Total Debt
OCUL
OCUL
TCI
TCI
Q4 25
$210.8M
Q3 25
$223.5M
Q2 25
$212.4M
Q1 25
$198.2M
Q4 24
$181.9M
Q3 24
$180.3M
Q2 24
$177.4M
Q1 24
$178.3M
Stockholders' Equity
OCUL
OCUL
TCI
TCI
Q4 25
$654.3M
$846.7M
Q3 25
$258.2M
$838.4M
Q2 25
$305.9M
$837.7M
Q1 25
$265.9M
$837.3M
Q4 24
$315.3M
$832.3M
Q3 24
$352.0M
$832.2M
Q2 24
$377.7M
$830.4M
Q1 24
$408.0M
$828.9M
Total Assets
OCUL
OCUL
TCI
TCI
Q4 25
$808.1M
$1.1B
Q3 25
$410.9M
$1.1B
Q2 25
$451.3M
$1.1B
Q1 25
$405.9M
$1.1B
Q4 24
$457.9M
$1.1B
Q3 24
$490.4M
$1.1B
Q2 24
$517.1M
$1.0B
Q1 24
$538.9M
$1.0B
Debt / Equity
OCUL
OCUL
TCI
TCI
Q4 25
0.25×
Q3 25
0.27×
Q2 25
0.25×
Q1 25
0.24×
Q4 24
0.22×
Q3 24
0.22×
Q2 24
0.21×
Q1 24
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
TCI
TCI
Operating Cash FlowLast quarter
$-54.2M
$-2.9M
Free Cash FlowOCF − Capex
$-57.1M
FCF MarginFCF / Revenue
-430.9%
Capex IntensityCapex / Revenue
21.4%
Cash ConversionOCF / Net Profit
-0.35×
TTM Free Cash FlowTrailing 4 quarters
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
TCI
TCI
Q4 25
$-54.2M
$-2.9M
Q3 25
$-50.7M
$8.2M
Q2 25
$-55.2M
$-2.9M
Q1 25
$-44.7M
$-7.4M
Q4 24
$-39.4M
$1.3M
Q3 24
$-36.6M
$13.7M
Q2 24
$-24.8M
$-511.0K
Q1 24
$-33.9M
$3.9M
Free Cash Flow
OCUL
OCUL
TCI
TCI
Q4 25
$-57.1M
Q3 25
$-56.7M
Q2 25
$-56.5M
Q1 25
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
Q2 24
$-25.5M
Q1 24
$-34.1M
FCF Margin
OCUL
OCUL
TCI
TCI
Q4 25
-430.9%
Q3 25
-390.0%
Q2 25
-419.7%
Q1 25
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
-155.4%
Q1 24
-231.1%
Capex Intensity
OCUL
OCUL
TCI
TCI
Q4 25
21.4%
Q3 25
41.2%
Q2 25
9.3%
Q1 25
18.1%
Q4 24
1.2%
Q3 24
0.6%
Q2 24
4.5%
Q1 24
1.7%
Cash Conversion
OCUL
OCUL
TCI
TCI
Q4 25
-0.35×
Q3 25
11.28×
Q2 25
-17.24×
Q1 25
-1.61×
Q4 24
12.13×
Q3 24
8.03×
Q2 24
-0.34×
Q1 24
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons